Fig. 5: RAD18 expression is associated with CSCs progression. | Cell Death & Disease

Fig. 5: RAD18 expression is associated with CSCs progression.

From: MicroRNA-379-5p attenuates cancer stem cells and reduces cisplatin resistance in ovarian cancer by regulating RAD18/Polη axis

Fig. 5

A Downregulation of RAD18 reduces the enrichment of CD44 + CD117+ cell populations within SKOV3 and OVCAR3 bulk cells following cisplatin treatment. CD44 + CD117+ cells were identified using flow cytometry, and the accompanying graph shows the percentage of CD44 + CD117+ cell enrichment. B The propidium iodide (PI) live-dead assay on SKOV3 and OVCAR3 spheroids showed enhanced cytotoxicity in cells with RAD18 downregulation after cisplatin treatment. C Downregulation of RAD18 was confirmed through western blotting in OV2008 and OVCAR3. D The downregulation of RAD18 in xenograft transplants resulted in reduced tumor size in athymic nude mice treated with either PBS or cisplatin (5 mg/kg body weight). E Tumor weights were measured in grams (gm) at the conclusion of the experiments (Bar, SD; Significance levels indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001).

Back to article page